156 related articles for article (PubMed ID: 9446566)
1. Structural determinants of ligand and cell surface binding of insulin-like growth factor-binding protein-3.
Firth SM; Ganeshprasad U; Baxter RC
J Biol Chem; 1998 Jan; 273(5):2631-8. PubMed ID: 9446566
[TBL] [Abstract][Full Text] [Related]
2. Modulation of human IGF binding protein-3 activity by structural modification.
Baxter RC; Firth SM
Prog Growth Factor Res; 1995; 6(2-4):215-22. PubMed ID: 8817664
[TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factor (IGF)-binding protein-3 mutants that do not bind IGF-I or IGF-II stimulate apoptosis in human prostate cancer cells.
Hong J; Zhang G; Dong F; Rechler MM
J Biol Chem; 2002 Mar; 277(12):10489-97. PubMed ID: 11784719
[TBL] [Abstract][Full Text] [Related]
4. Substitutions for hydrophobic amino acids in the N-terminal domains of IGFBP-3 and -5 markedly reduce IGF-I binding and alter their biologic actions.
Imai Y; Moralez A; Andag U; Clarke JB; Busby WH; Clemmons DR
J Biol Chem; 2000 Jun; 275(24):18188-94. PubMed ID: 10766744
[TBL] [Abstract][Full Text] [Related]
5. Characterisation of recombinant glycosylation variants of insulin-like growth factor binding protein-3.
Firth SM; Baxter RC
J Endocrinol; 1999 Mar; 160(3):379-87. PubMed ID: 10076184
[TBL] [Abstract][Full Text] [Related]
6. Binding of mutants of human insulin-like growth factor II to insulin-like growth factor binding proteins 1-6.
Bach LA; Hsieh S; Sakano K; Fujiwara H; Perdue JF; Rechler MM
J Biol Chem; 1993 May; 268(13):9246-54. PubMed ID: 7683646
[TBL] [Abstract][Full Text] [Related]
7. Substitution of specific amino acids in insulin-like growth factor (IGF) binding protein 5 alters heparin binding and its change in affinity for IGF-I response to heparin.
Arai T; Clarke J; Parker A; Busby W; Nam T; Clemmons DR
J Biol Chem; 1996 Mar; 271(11):6099-106. PubMed ID: 8626396
[TBL] [Abstract][Full Text] [Related]
8. Binding sites and binding properties of binary and ternary complexes of insulin-like growth factor-II (IGF-II), IGF-binding protein-3, and acid-labile subunit.
Hashimoto R; Ono M; Fujiwara H; Higashihashi N; Yoshida M; Enjoh-Kimura T; Sakano K
J Biol Chem; 1997 Oct; 272(44):27936-42. PubMed ID: 9346943
[TBL] [Abstract][Full Text] [Related]
9. Purified rat acid-labile subunit and recombinant human insulin-like growth factor (IGF)-binding protein-3 can form a 150-kilodalton binary complex in vitro in the absence of IGFs.
Lee CY; Rechler MM
Endocrinology; 1995 Nov; 136(11):4982-9. PubMed ID: 7588232
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of insulin-like growth factor (IGF)-binding protein-3 and its proteolytic fragments on ligand binding, cell surface association, and IGF-I receptor signaling.
Devi GR; Yang DH; Rosenfeld RG; Oh Y
Endocrinology; 2000 Nov; 141(11):4171-9. PubMed ID: 11089550
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the affinities of insulin-like growth factor (IGF)-binding proteins 1-4 for IGF-I, IGF-II, IGF-I/insulin hybrid, and IGF-I analogs.
Oh Y; Müller HL; Lee DY; Fielder PJ; Rosenfeld RG
Endocrinology; 1993 Mar; 132(3):1337-44. PubMed ID: 7679979
[TBL] [Abstract][Full Text] [Related]
12. Solid-phase assay for insulin-like growth factor (IGF) binding to IGF-binding protein-3: application to the study of the effects of antibodies and heparin.
Koedam JA; Hoogerbrugge CM; van Buul-Offers SC; Van den Brande JL
J Endocrinol; 1997 Apr; 153(1):87-97. PubMed ID: 9135573
[TBL] [Abstract][Full Text] [Related]
13. Amino- and carboxyl-terminal fragments of insulin-like growth factor (IGF) binding protein-3 cooperate to bind IGFs with high affinity and inhibit IGF receptor interactions.
Payet LD; Wang XH; Baxter RC; Firth SM
Endocrinology; 2003 Jul; 144(7):2797-806. PubMed ID: 12810533
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor (IGF)-binding protein 5 forms an alternative ternary complex with IGFs and the acid-labile subunit.
Twigg SM; Baxter RC
J Biol Chem; 1998 Mar; 273(11):6074-9. PubMed ID: 9497324
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and characterization of biotinylated forms of insulin-like growth factor-1: topographical evaluation of the IGF-1/IGFBP-2 AND IGFBP-3 interface.
Robinson SA; Rosenzweig SA
Biochemistry; 2004 Sep; 43(36):11533-45. PubMed ID: 15350139
[TBL] [Abstract][Full Text] [Related]
16. Interaction of insulin-like growth factor II (IGF-II) with multiple plasma proteins: high affinity binding of plasminogen to IGF-II and IGF-binding protein-3.
Oesterreicher S; Blum WF; Schmidt B; Braulke T; Kübler B
J Biol Chem; 2005 Mar; 280(11):9994-10000. PubMed ID: 15642732
[TBL] [Abstract][Full Text] [Related]
17. Mutagenesis of basic amino acids in the carboxyl-terminal region of insulin-like growth factor binding protein-5 affects acid-labile subunit binding.
Firth SM; Clemmons DR; Baxter RC
Endocrinology; 2001 May; 142(5):2147. PubMed ID: 11316783
[TBL] [Abstract][Full Text] [Related]
18. Role for membrane and secreted insulin-like growth factor-binding protein-2 in the regulation of insulin-like growth factor action in lung tumors.
Reeve JG; Morgan J; Schwander J; Bleehen NM
Cancer Res; 1993 Oct; 53(19):4680-5. PubMed ID: 7691401
[TBL] [Abstract][Full Text] [Related]
19. Binding characteristics of pro-insulin-like growth factor-II from cancer patients: binary and ternary complex formation with IGF binding proteins-1 to -6.
Bond JJ; Meka S; Baxter RC
J Endocrinol; 2000 May; 165(2):253-60. PubMed ID: 10810289
[TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factor binding protein-3: factors affecting binary and ternary complex formation.
Holman SR; Baxter RC
Growth Regul; 1996 Mar; 6(1):42-7. PubMed ID: 8717449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
